Impact of initiatinG bioLogics In patients with severe asThma on long-Term OCS or frEquent Rescue steroids (GLITTER): data from the International Severe Asthma Registry

Wenjia Chen, Trung N Tran, Mohsen Sadatsafavi, Ruth Murray, Nigel Chong Boon Wong, Nasloon Ali, Con Ariti, Lakmini Bulathsinhala, Esther Garcia Gil, J Mark FitzGerald, Marianna Alacqua, Mona Al-Ahmad, Alan Altraja, Riyad Al-Lehebi, Mohit Bhutani, Leif Bjermer, Anne-Sofie Bjerrum, Arnaud Bourdin, Anna von Bülow, John BusbyGiorgio Walter Canonica, Victoria Carter, George C Christoff, Borja G Cosio, Richard W Costello, João A Fonseca, Peter G Gibson, Kwang-Ha Yoo, Liam G Heaney, Enrico Heffler, Mark Hew, Ole Hilberg, Flavia Hoyte, Takashi Iwanaga, Rupert C Jones, Mariko Siyue Koh, Piotr Kuna, Désirée Larenas-Linnemann, Sverre Lehmann, Lauri Lehtimäki, Juntao Lyu, Bassam Mahboub, Jorge Maspero, Andrew N Menzies-Gow, Anthony Newell, Concetta Sirena, Nikolaos G Papadopoulos, Andriana I Papaioannou, Luis Perez-de-Llano, Diahn-Warng Perng Steve, Matthew Peters, Paul E Pfeffer, Celeste M Porsbjerg, Todor A Popov, Chin Kook Rhee, Sundeep Salvi, Camille Taillé, Christian Taube, Carlos A Torres-Duque, Charlotte Ulrik, Seung-Won Ra, Eileen Wang, Michael E Wechsler, David B Price

Research output: Contribution to journalArticlepeer-review


BACKGROUND: Effectiveness of biologics has neither been established in patients with high oral corticosteroid exposure (HOCS), nor been compared to effectiveness of continuing with HOCS alone.

OBJECTIVE: To examine the effectiveness of initiating biologics in a large, real-world cohort of adult patients with severe asthma and HOCS.

METHODS: This was a propensity-score-matched, prospective cohort study using data from the International Severe Asthma Registry ( Between January 2015 and February 2021, patients with severe asthma and HOCS (long-term OCS ≥1 year or ≥4 courses of rescue OCS within a 12-month period) were identified. Biologic initiators were identified and, using propensity scores, matched 1:1 with non-initiators. The impact of biologic initiation on asthma outcomes were assessed using generalized linear models.

RESULTS: We identified 996 matched pairs of patients. Both groups improved over the 12-month follow-up period, but improvement was greater for biologic-initiators. Biologic initiation was associated with a 72.9% reduction in the average number of exacerbations/year versus non-initiators (0.64 vs 2.06, rate ratio: 0.27 [95%CI, 0.10, 0.71]). Biologic initiators were 2.2 times more likely than non-initiators to take a daily long-term OCS dose <5mg (probability: 49.6% vs 22.5%; p=0.002) and had a lower risk of asthma-related emergency department visits (relative risk: 0.35 [95% CI: 0.21, 0.58]; rate ratio 0.26 [0.14, 0.48]) and hospitalizations (relative risk: 0.31 [95% CI: 0.18, 0.52]; rate ratio 0.25 [0.13, 0.48]).

CONCLUSIONS: In a real-world setting, including patients with severe asthma and HOCS from 19 countries, and within an environment of clinical improvement, initiation of biologics was associated with further improvements across multiple asthma outcomes, including exacerbation rate, OCS exposure, and healthcare resource utilization.

Original languageEnglish
JournalJournal of Allergy and Clinical Immunology: In Practice
Early online date08 Jun 2023
Publication statusEarly online date - 08 Jun 2023

Bibliographical note

Copyright © 2023. Published by Elsevier Inc.


Dive into the research topics of 'Impact of initiatinG bioLogics In patients with severe asThma on long-Term OCS or frEquent Rescue steroids (GLITTER): data from the International Severe Asthma Registry'. Together they form a unique fingerprint.

Cite this